血清中人附睾分泌蛋白4和CA125联合检测在卵巢癌发病风险预测中的价值

目的探讨血清中人附睾分泌蛋白4(HE4)和糖类抗原CA125联合检测在卵巢癌发病风险预测中的价值。方法用化学发光法检测108例卵巢癌患者、55例卵巢良性疾病患者及50例健康对照者血清中HE4和CA125水平,对结果进行比较分析。结果①卵巢癌患者HE4和CA125水平明显高于卵巢良性疾病和健康对照者(均P0.05)。②HE4和CA125单独检测对卵巢癌诊断的敏感度无差异(P0.05)。③对于卵巢疾病患者,未绝经者和绝经者卵巢癌发病风险计算(ROMA)值分别大于7.4%和25.3%时,可能存在卵巢癌发病高风险。通过HE4和CA125计算ROMA值,卵巢癌未绝经组和绝经组敏感度均高于同类组HE4、CA125单独检测的敏感度,P0.05。结论 HE4和CA125单独检测对卵巢癌诊断的敏感度无差异,两者联合检测可以提高诊断能力。

Value of joint detection of HE4 and CA125 in the risk prediction of ovarian cancer

[Objective]To discuss the value of joint detection of HE4 and CA125 in the risk prediction of ovarian cancer.[Methods]The serum HE4 and CA125 level were detected on 108 cases of ovarian cancer patients,55 cases of the ovary benign disease and 50 healthy controls with chemiluminescence,the results were compared.[Results]① The HE4 and CA125 level of ovarian cancer patients was obviously higher than the that of the ovary benign disease patients and the controls（both P0.05）.② HE4 single test susceptibility was no significantly different with CA125 on diagnosis of ovarian cancer（P0.05）.③ For ovary disease,the ovarian cancer ROMA value of the premenopausal patients and menopause patients was higher than 7.4% and 25.3%,respectively.There might be a high risk of ovarian cancer.Through calculation of ROMA value by HE4 and CA125,the susceptibility of premenopausal group and the menopause group was higher than those with single HE4 and CA125 detection（P0.05）.[Conclusion]The susceptibility of single HE4 test is no significantly different with CA125 on diagnosis of ovarian cancer,joint inspection can enhance the diagnostic capacity.